Kyorin Pharmaceutical Co., Ltd. (KYRNF)
OTC GREY 
JPX Primary OTC GREY Summary
Kyorin Pharmaceutical Co., Ltd. (KYRNF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kyorin Pharmaceutical Co., Ltd. ever had a stock split?
Kyorin Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Yutaka Ogihara CEO | OTC GREY Exchange | JP3247090008 ISIN |
| Japan Country | 1,998 Employees | 29 Sep 2026 Last Dividend | 25 Sep 2001 Last Split | - IPO Date |
Overview
KYORIN Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, is a multifaceted pharmaceutical company that operates globally. Founded in 1923, it originally bore the name KYORIN Holdings, Inc. This company is dedicated to the research, development, manufacture, and sale of both ethical (prescription) and generic drugs. With a presence both in Japan and internationally, KYORIN Pharmaceutical stands out as a key player in the pharmaceutical industry, providing a wide range of healthcare solutions across various therapeutic areas. Additionally, it offers subcontracted drug manufacturing services, participates in the discovery and evaluation of candidate compounds, and actively engages in the research and analysis of technologies from other companies, including the collection of information related to clinical trials.
Products and Services
- Flutiform
- Lyfuna
- Desalex
- Beova, Uritos, and Imidafenacin KYORIN
- Lasvic
- Pentasa
- Nasonex and Mometasone KYORIN
- Kipres
- Mucodyne
- Montelukast KM
- GeneSoC
- Rubysta
- Milton
- Over-the-Counter Drugs, Prescription Medicines and Quasi-Drugs, Diagnostics, and Industrial Chemicals
- Subcontracted Drug Manufacturing Services
A combination drug used for the treatment of asthma, showcasing KYORIN's commitment to respiratory care.
Targets cough treatment, providing relief and support for respiratory conditions.
An antiallergic agent, part of KYORIN's array of solutions for treating allergic reactions.
Therapeutic agents directed at managing symptoms associated with overactive bladder, demonstrating KYORIN's focus on urological health.
A quinolone synthetic antibacterial agent, indicating KYORIN's involvement in addressing bacterial infections.
A remedy utilized for the treatment of ulcerative colitis and Crohn's disease, reflecting KYORIN's engagement with gastrointestinal disorders.
Employed as therapeutic agents for allergic rhinitis, these drugs underline KYORIN's dedication to respiratory health.
A leukotriene receptor antagonist used for anti-bronchial asthma and allergic rhinitis, further showcasing the company’s commitment to treating respiratory conditions.
A mucoregulating drug, enhancing KYORIN’s portfolio in addressing respiratory diseases by facilitating mucus clearance.
Another significant addition for the treatment of bronchial asthma and allergic rhinitis, indicating a strong focus on respiratory health solutions.
A real-time PCR system, representing KYORIN’s strides in biotechnological advancements for diagnostic purposes.
A disinfectant cleaner, part of KYORIN's range of products aimed at infection control and safety.
This disinfectant underscores the company's dedication to providing solutions for maintaining hygienic environments.
KYORIN offers a wide array of health care products aside from their main pharmaceutical lineup, including self-care medications, diagnostics, and various chemicals for industrial use.
The company also provides pharmaceutical manufacturing services to other entities, showing KYORIN's versatility and capacity within the pharmaceutical industry.
